Save up -80% on Eltrombopag
Note: this is a drug discount program, not an insurance plan.
2018 Price of Eltrombopag
* price without discount in nearest pharmacy. Price may vary.
We offer free Eltrombopag coupons and discounts that may help you save up to 80% off the retail price in your local pharmacy. Just print your coupon! It’s ready to use and never expire. Present your discount card in most local pharmacies to get a discount on Eltrombopag every time. What are you waiting for? Claim your prescription drug card now!
Eltrombopag volume of distribution
Based on a radiolabel study, the concentration of eltrombopag in blood cells is approximately 50% to 79% of plasma concentrations.
Discount Cards 16,000+
Clients Benefit 29%
Total savings $4,735,080
What is Eltrombopag
Eltrombopag is used to treat low blood platelet counts in adults with chronic immune (idiopathic) thrombocytopenia (ITP), when certain other medicines, or surgery to remove the spleen, have not worked well enough. ITP is a condition that may cause unusual bruising or bleeding due to an abnormally low number of platelets in the blood. Eltrombopag has also been recently approved (late 2012) for the treatment of thrombocytopenia (low blood platelet counts) in patients with chronic hepatitis C to allow them to initiate and maintain interferon-based therapy.
Eltrombopag mechanism of action
Eltrombopag is an orally bioavailable, small-molecule TPO-receptor agonist that interacts with the transmembrane domain of the human TPO-receptor. Eltrombopag is a stimulator of STAT and JAK phosphorylation. Unlike recombinant TPO or romiplostim, Eltrombopag does not activate the AKT pathway in any way. It should be noted that when given to patients with aplastic anemia, other lineages besides platelet count were increased, suggesting that either eltrombopag enhanced the effect of TPO in vivo; or there is a yet uncovered mechanism of action at work.
Dosage forms of Eltrombopag
|Tablet, film coated||oral||100 mg/1|
|Tablet, film coated||oral||12.5 mg/1|
|Tablet, film coated||oral||25 mg/1|
Glaxo Smith Kline Llc
Humans and other mammals
Indication of Eltrombopag
Thrombopoietin receptor agonists are pharmaceutical agents that stimulate platelet production in the bone marrow. In this, they differ from the previously discussed agents that act by attempting to curtail platelet destruction.
Toxicity of Eltrombopag
Eltrombopag may cause hepatotoxicity, especially if administered in combination with interferon and ribavirin in patients with chronic hepatitis C (may increase the risk of hepatic decompensation).
RX24 Drugs Disclaimer: before buying a Eltrombopag on prescription, consult your healthcare provider. Content on this page is provided for informational purposes only. Any use of this information is at your own risk.